These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Cancer Treat Rep; 1984 Nov; 68(11):1403-5. PubMed ID: 6541973 [No Abstract] [Full Text] [Related]
3. Therapy for metastatic melanoma: effective combination of dacarbazine, carmustine, cisplatin and tamoxifen. Fierro MT, Bertero M, Novelli M, Appino A, Doveil GC, Colonna S, Bernengo MG. Melanoma Res; 1993 Apr; 3(2):127-31. PubMed ID: 8518551 [Abstract] [Full Text] [Related]
4. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma. Tan EH, Ang PT. Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255 [Abstract] [Full Text] [Related]
5. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Lattanzi SC, Tosteson T, Chertoff J, Maurer LH, O'Donnell J, LeMarbre PJ, Mott L, DelPrete SA, Forcier RJ, Ernstoff MS. Melanoma Res; 1995 Oct; 5(5):365-9. PubMed ID: 8541728 [Abstract] [Full Text] [Related]
6. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma. Su PJ, Chen JS, Liaw CC, Chang HK, Wang HM, Yang TS, Lin YC, Liau CT, Yang HY, Yeh KY, Ho MM, Chang NJ, Wang CH, Chang JW. Chang Gung Med J; 2011 Oct; 34(5):478-86. PubMed ID: 22035892 [Abstract] [Full Text] [Related]
7. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. Serrone L, Zeuli M, Sega FM, Cognetti F. J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932 [Abstract] [Full Text] [Related]
8. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K. J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240 [Abstract] [Full Text] [Related]
9. What can we learn from phase II adjuvant trials in melanoma? Keilholz U, Suciu S, Eggermont AM. Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660 [No Abstract] [Full Text] [Related]
10. The Dartmouth Regimen: gone or going strong? McClay EF, Berd D, Mastrangelo MJ. Cancer Invest; 1998 Jul; 16(6):421-3. PubMed ID: 9679534 [No Abstract] [Full Text] [Related]
11. Sustained complete remission after chemobiohormonal therapy for metastatic melanoma. Stein ME, Bernstein Z, Drumea K, Zalik M, Shklar Z, Steiner M, Haim N. Am J Clin Oncol; 1999 Feb; 22(1):62-4. PubMed ID: 10025383 [Abstract] [Full Text] [Related]
12. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409 [Abstract] [Full Text] [Related]
13. Bleomycin, carmustine, vincristine, and dacarbazine in patients with metastatic malignant melanoma. Cohen SM, Ohnuma T, Cheung T, Holland JF. Cancer Treat Rep; 1983 Oct; 67(10):947-8. PubMed ID: 6194881 [No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS. Ann Plast Surg; 1992 Jan; 28(1):60-4. PubMed ID: 1642408 [Abstract] [Full Text] [Related]
15. Three-drug combination of cisplatin, dacarbazine, and tamoxifen in metastatic malignant melanoma. Chmielowska E, Potemski P, Pluzańska A. J Clin Oncol; 1995 Aug; 13(8):2146-7. PubMed ID: 7636562 [No Abstract] [Full Text] [Related]
16. Malignant melanoma: primary presentation in bone marrow and lymph node. Basile M, Moskowitz B, Harris J, Blumberg N, Bennett JM. Med Pediatr Oncol; 1992 Aug; 20(1):75-7. PubMed ID: 1727216 [Abstract] [Full Text] [Related]
17. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349 [Abstract] [Full Text] [Related]
18. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? McClay EF, McClay ME. J Clin Oncol; 1994 Mar; 12(3):617-26. PubMed ID: 8120562 [Abstract] [Full Text] [Related]
19. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR. Thromb Haemost; 2003 Feb; 89(2):405-7. PubMed ID: 12574822 [No Abstract] [Full Text] [Related]
20. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. Propper DJ, Braybrooke JP, Levitt NC, O'Byrne K, Christodoulos K, Han C, Talbot DC, Ganesan TS, Harris AL. Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287 [Abstract] [Full Text] [Related] Page: [Next] [New Search]